Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 17/20 | 0.74 |
| ▸ | CPT1B | Q92523 | 17/20 | 0.74 |
| ▸ | CPT2 | P23786 | 13/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835855 | 0.94 | CPT1A (0.70) | CPT1ACPT1BCPT2ALDH1A1KMT2A | |
| SCHEMBL2900551 | 0.94 | CPT1A (0.76) | CPT1ACPT1BCPT2ALDH1A1KMT2A | |
| SCHEMBL3835852 | 0.92 | CPT1A (0.74) | CPT1ACPT1BCPT2ALDH1A1KMT2A | |
| SCHEMBL2907983 | 0.92 | CPT1A (0.74) | CPT1ACPT1BCPT2ALDH1A1KMT2A | |
| SCHEMBL2904140 | 0.89 | CPT1A (0.76) | CPT1ACPT1BCPT2ALDH1A1KMT2A | |
| SCHEMBL3841719 | 0.88 | CPT1A (0.74) | CPT1ACPT1BCPT2ALDH1A1KMT2A | |
| SCHEMBL3841723 | 0.87 | CPT1A (0.73) | CPT1ACPT1BCPT2ALDH1A1KMT2A | |
| SCHEMBL2898641 | 0.85 | CPT1A (1.00) | CPT1ACPT1BCPT2ALDH1A1 | |
| SCHEMBL2903506 | 0.84 | CPT1A (0.84) | CPT1ACPT1BCPT2ALDH1A1 | |
| SCHEMBL3565296 | 0.82 | CPT1A (0.75) | CPT1ACPT1BCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799933-B2 | Sulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | CPT1A, SULT2A1, SULT1A1 | CPT1A 1/4885CPT1B 5/4885CPT2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.